Tag: Gene Therapy Supply Chain

Last week, during our weekly industry update sessions, our prime focus was to understand the recent innovations in the field of cell therapy manufacturing. We were also looking out for players that are driving these innovations. To start with, the first news that caught our attention was Novartis’ decision to sidestep Europe travel ban to

As we enter 2020, one drug class that is set to take-off is gene therapy. With three approvals (Zolgensma® (US), Zynteglo™ (Europe) and Beperminogene Perplasmid (Japan), 2019 was a break out year for gene therapy developers. The $16 billion-plus investment by various investors finally seems to be paying off as we enter 2020 with a